精密混合风险模型用于识别子群体中的不良药物事件,使用案例交叉设计
Yi Shi1, Michael T Eadon2, Yao Chen1
1Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA.
Statistics in medicine
|September 19, 2024
概括
这项研究引入了一种新的模型,使用行政索赔数据在特定患者群体中寻找不良药物事件 (ADE) 信号. 精密混合风险模型 (PMRM) 有效地识别了亚种群独特的风险,提高了患者的安全性.
科学领域:
- 药物监督和药物流行病学
- 生物统计和健康数据科学 数据科学
- 计算健康和临床信息学
背景情况:
- 使用真实数据的药监测研究对于检测不良药物事件至关重要.
- 然而,在特定的亚群体中,ADE的风险需要加强审查,以保护脆弱的个体.
- 适用于行政索赔数据的案例交叉设计提供了一种用于检测ADE的方法,同时控制混效应.
研究的目的:
- 提出一种新的精密混合风险模型 (PMRM) 用于在子群体内识别ADE信号.
- 为了利用病例交叉设计,在脆弱的患者群体中增强ADE信号检测.
- 为了控制特定亚群的ADE信号识别中的错误发现率 (FDR) 和混效应.
主要方法:
- 在案例交叉框架内实施精密混合风险模型 (PMRM).
- 将PMRM应用于大规模的行政索赔数据.
- 通过人口统计,并发症和诊断代码定义的亚种群的ADE信号分析.
主要成果:
- 该PMRM成功地在各种亚群中识别了ADE信号.
- 某些药物表明ADE风险仅在子群体中存在,而不是在一般人群中.
- 与McNemar的测试相比,PMRM有效地控制了FDR,并且在检测真正的ADE信号方面表现出更高的灵敏度.
结论:
- 该PMRM有效地识别了从广泛的ADE-亚种群-药物组合中特定于亚种群的ADE信号.
- 该模型控制了FDR和混效应,提高了ADE信号检测的可靠性.
- 这种方法提高了在脆弱患者群体中检测和预防ADEs的能力.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
239
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
239
01:23Mechanistic Models: Compartment Models in Individual and Population Analysis
32
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
32
01:19Pharmacovigilance
786
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
786
01:12Hazard Ratio
92
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
92
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
01:21Mechanistic Models: Overview of Compartment Models
72
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
72